Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy

Journal of Clinical Oncology

Volumn 18, Issue 10, 2000, Pages 2095-2103

  Shepherd, Frances A ^a   Dancey, Janet ^a   Ramlau, Rodryg ^a   Mattson, Karin ^a   Gralla, Richard ^a   O'Rourke, Mark ^a   Levitan, Nathan ^a   Gressot, Laurent ^a   Vincent, Mark ^a   Burkes, Ronald ^a   Coughlin, Susan ^a   Kim, Yong ^a   Berille, Jocelyne ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0034069620     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.10.2095     Document Type: Article

References (22)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995
2. Shepherd FA: Chemotherapy for non-small cell lung cancer: Have we reached a new plateau? Semin Oncol 26:3-11, 1999
3. Fossella FV, Lee JS, Hong WK: Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24:455-462, 1997
4. Burris HA, Eckardt J, Fields S, et al: Phase II trials of Taxotere in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 12:335a, 1993 (abstr 1116)
5. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
6. Gandara DR, Vokes E, Green M, et al: Docetaxel (Taxotere®) in platinum-treated non-small-cell lung cancer (NSCLC): Confirmation of prolonged survival in a multi-center trial. Proc Am Soc Clin Oncol 16:454a, 1997 (abstr 1632)
7. Robinet G, Kleisbaurer JP, Thomas P, et al: Phase II study of Taxotere (docetaxel) in advanced or metastatic non-small cell lung cancer previously treated with platinum. Ann Oncol 7:96-97, 1996 (suppl 5, abstr 458P)
8. Robinet G, Kleisbauer JP, Thomas P, et al: Phase II study of docetaxel (Taxotere) in first-and second-line NSCLC. Proc Am Soc Clin Oncol 16:480a, 1997 (abstr 1726)
9. Mattson K, Le Chevalier T, Stupp R, et al: Preliminary report of Phase II study of docetaxel (Taxotere®) in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 7:429a, 1996 (suppl 5, abstr)
10. Le Chevalier T: Docetaxel: Meeting the challenge of non-small cell lung cancer management. Anticancer Drugs 6:13-17, 1995 (suppl 4)
11. Yokoyama A, Kurita Y, Watanabe K: Early Phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer: Docetaxel Cooperative Study Group for Lung Cancer. Gan To Kagaku Ryoho 21:2609-2616, 1994 (in Japanese)
12. Pronzato P, Landucci M, Vaira F, et al: Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res 14:1413-1416, 1994
13. Rinaldi M, Della Giulia M, Venturo I, et al: Vinorelbine as single agent in the treatment of advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 13:360a, 1994 (abstr 1212)
14. Sandoro A, Maiorinol Sandoro M: Second-line treatment with vinorelbine in the weekly monotherapy chemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 11:130, 1994 (suppl 1, abstr 497)
15. Socinski MA, Steagall A: A phase II trial of 96-hour paclitaxel infusion in patients with non-small-cell lung cancer failing previous platinum-based or short-infusion paclitaxel therapy. Proc Am Soc Clin Oncol 16:482a, 1997 (abstr 1735)
16. Ruckdeschel J, Wagner H, Williams C, et al: Second-line chemotherapy for resistant metastatic non-small-cell lung cancer: The role of Taxol. Proc Am Soc Clin Oncol 13:357a, 1994 (abstr 1200)
17. Murphy WK, Winn RJ, Huber M, et al: Phase II study of taxol in patients with non-small cell lung cancer who have failed platinum-containing chemotherapy. Proc Am Soc Clin Oncol 13:363a, 1994 (abstr 1224)
18. Hainsworth JD, Thompson SD, Greco FA: Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13:1609-1614, 1995
19. Rossi A, Perrone F, Barletta R, et al: Activity of gemcitabine in cisplatin-pretreated patients with advanced non-small-cell lung cancer: A phase II trial. Proc Am Soc Clin Oncol 18:484a, 1999 (abstr 1868)
20. 2) versus vinorelbine (V) or ifosfamide (I) in non-small-cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 17:483a, 1998 (abstr 1859)
21. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy: A phase II single-center study. J Clin Oncol 17:1127-1131, 1999
22. Ellis PA, Smith IE, Hardy JR, et al: Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 71:366-370, 1995